文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

霉酚酸酯或硫唑嘌呤用于慢性过敏性肺炎的管理

Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.
PubMed 文献 · Chest · 2016-11-03
一句话结论回顾性多中心研究显示,霉酚酸酯或硫唑嘌呤治疗慢性过敏性肺炎与DLCO一年内改善4.2%相关,但FVC无显著改善。

该回顾性研究从四个间质性肺病中心纳入70例慢性过敏性肺炎患者,其中51例接受霉酚酸酯、19例接受硫唑嘌呤治疗,中位随访11个月。治疗前FVC和DLCO占预计值百分比分别以每月0.12%和0.10%的速度下降。线性混合效应模型调整年龄、性别、吸烟史和泼尼松使用后显示,治疗与FVC改善无显著关联(1年时0.5%,P=.46),但与DLCO显著改善4.2%相关(P<.001)。霉酚酸酯亚组1年结果类似,FVC非显著增加1.3%(P=.103),DLCO增加3.9%(P<.001)。作者结论认为霉酚酸酯或硫唑嘌呤与慢性过敏性肺炎患者DLCO改善相关,需要前瞻性随机试验验证其有效性。

要点

  • 治疗前FVC和DLCO占预计值百分比分别以每月0.12%(P<.001)和0.10%(P<.001)的速度下降。
  • 霉酚酸酯或硫唑嘌呤治疗1年与DLCO显著改善4.2%(P<.001)相关。
  • 治疗1年与FVC改善无显著关联(0.5%,P=.46)。
  • 霉酚酸酯亚组1年FVC非显著增加1.3%(P=.103),DLCO增加3.9%(P<.001)。
  • 作者结论认为需要前瞻性随机试验验证霉酚酸酯或硫唑嘌呤对慢性过敏性肺炎的有效性。

适用人群与场景

  • 从四个间质性肺病中心回顾性识别的慢性过敏性肺炎患者,接受霉酚酸酯或硫唑嘌呤治疗。

处置流程与药物剂量

  • 51例接受霉酚酸酯治疗,19例接受硫唑嘌呤治疗;分析中调整了年龄、性别、吸烟史和泼尼松使用。

研究设计与关键结果

  • 回顾性研究,四个间质性肺病中心,纳入70例慢性过敏性肺炎患者,51例用霉酚酸酯、19例用硫唑嘌呤,中位随访11个月。
  • 治疗前FVC和DLCO占预计值百分比分别以每月0.12%(P<.001)和0.10%(P<.001)下降。
  • 线性混合效应模型调整年龄、性别、吸烟史和泼尼松使用后,治疗与FVC改善无显著关联(1年时0.5%,P=.46),与DLCO显著改善4.2%(P<.001)相关。
  • 霉酚酸酯亚组治疗1年FVC非显著增加1.3%(P=.103),DLCO增加3.9%(P<.001)。

证据类型、等级与局限

  • 回顾性研究,来自四个间质性肺病中心。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为霉酚酸酯或硫唑嘌呤与慢性过敏性肺炎患者DLCO改善相关。
  • 作者结论认为需要前瞻性随机试验验证霉酚酸酯或硫唑嘌呤对慢性过敏性肺炎的有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The treatment of chronic hypersensitivity pneumonitis (cHP) often includes systemic oral corticosteroids, but the optimal pharmacologic management remains unclear. The morbidity associated with prednisone has motivated the search for alternative therapies. We aimed to determine the effect of treatment with mycophenolate mofetil (MMF) or azathioprine (AZA) on lung function in patients with cHP.

METHODS: Patients with cHP treated with either MMF or AZA were retrospectively identified from four interstitial lung disease centers. Change in lung function before and after treatment initiation was analyzed using linear mixed-effects modeling (LMM), adjusting for age, sex, smoking history, and prednisone use.

RESULTS: Seventy patients were included: 51 were treated with MMF and 19 with AZA. Median follow-up after treatment initiation was 11 months. Prior to treatment initiation, FVC and diffusion capacity of the lung for carbon monoxide (Dlco) % predicted were declining at a mean rate of 0.12% (P < .001) and 0.10% (P < .001) per month, respectively. Treatment with either MMF or AZA was not associated with improved FVC (0.5% at 1 year; P = .46) but was associated with a statistically significant improvement in Dlco of 4.2% (P < .001) after 1 year of treatment. Results were similar in the subgroup of patients treated with MMF for 1 year; the FVC increased nonsignificantly by 1.3% (P = .103) and Dlco increased by 3.9% (P < .001).

CONCLUSIONS: Treatment with MMF or AZA is associated with improvements in Dlco in patients with cHP. Prospective randomized trials are needed to validate their effectiveness for cHP.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Morisset J, Johannson KA, Vittinghoff E, et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2016. PMID: 27816444. doi:10.1016/j.chest.2016.10.029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。